Aurinia Pharmaceuticals Inc. (AUPH) Stock Analysis
Last updated Oct 27, 2026
Published Opportunity
This stock was published as a Compound Radar opportunity on Jun 26, 2026. Performance is tracked publicly from the original signal.
Health Check
Last analyzed Oct 23, 2026
- Financial Health 85
- Profitability 95
- Business Quality 75
- Balance Sheet 65
- Cash Flow 80
Why this rating?
Health 83/100 — Elite Quality
Worth tracking, but timing is mixed — not a clear setup yet.
Company overview
Aurinia Pharmaceuticals Inc. (AUPH) is a Biotechnology company in the Healthcare sector. Compound Radar rates Aurinia Pharmaceuticals Inc. 83/100 (Elite Quality) due to high business quality, strong revenue growth, and manageable leverage.
Investment profile
- Quality High
- Growth Strong
- Balance Sheet Adequate
- Valuation Attractive
Financial highlights
Valuation
- P/E 7.57
- Forward P/E 14.77
- EV/Revenue 6.15
Profitability
- Revenue Growth 18.9%
- Gross Margin 77.9%
- Operating Margin 55.7%
- Net Margin 100.8%
- ROE 66.1%
Financial strength
- Cash $443.02M
- Debt $64.14M
- Net Cash $378.89M
- Free Cash Flow $135.41M
- Current Ratio 5.42
Similar companies
Peers in Biotechnology, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Incyte Corporation Biotechnology INCY$116.60 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Catalyst Pharmaceuticals Inc Biotechnology CPRX$31.49 81 Health 81 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- ADMA Biologics, Inc. Biotechnology ADMA$11.06 80 Health 80 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Innoviva, Inc. Biotechnology INVA$20.94 80 Health 80 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Strong Entry Strong EntryTiming looks favorable across trend, momentum, valuation, support, and catalysts.
- Alnylam Pharmaceuticals, Inc. Biotechnology ALNY$226.79 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Halozyme Therapeutics, Inc. Biotechnology HALO$128.50 77 Health 77 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Vertex Pharmaceuticals Incorporated Biotechnology VRTX$521.03 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Harmony Biosciences Holdings, Inc. Biotechnology HRMY$37.95 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Aurinia Pharmaceuticals Inc. (AUPH).